1. Home
  2. STTK vs IGR Comparison

STTK vs IGR Comparison

Compare STTK & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

BUY

Current Price

$5.65

Market Cap

652.4M

Sector

Health Care

ML Signal

BUY

Logo CBRE Global Real Estate Income Fund of Beneficial Interest

IGR

CBRE Global Real Estate Income Fund of Beneficial Interest

HOLD

Current Price

$11.13

Market Cap

693.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
IGR
Founded
2016
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
652.4M
693.0M
IPO Year
2020
2003

Fundamental Metrics

Financial Performance
Metric
STTK
IGR
Price
$5.65
$11.13
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
★ $15.22
N/A
AVG Volume (30 Days)
★ 1.1M
411.8K
Earning Date
11-05-2026
01-01-0001
Dividend Yield
N/A
★ 13.93%
EPS Growth
★ 53.02
N/A
EPS
N/A
★ N/A
Revenue
★ $1,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.70
$4.15
52 Week High
$8.33
$13.67

Technical Indicators

Market Signals
Indicator
STTK
IGR
Relative Strength Index (RSI) 35.85 61.20
Support Level $3.55 $4.54
Resistance Level $7.83 $13.67
Average True Range (ATR) 0.46 0.18
MACD -0.01 -0.36
Stochastic Oscillator 5.65 0.00

Price Performance

Historical Comparison
STTK
IGR

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About IGR CBRE Global Real Estate Income Fund of Beneficial Interest

CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.

Share on Social Networks: